您的购物车当前为空
别名 苯并[a]芘, 苯并(a)芘, 3,4-Benzopyrene
Benzo[a]pyrene(3,4-Benzopyrene)在动物模型中表现出肺致癌性,常用于肺癌造模及化学预防研究。
![Benzo[a]pyrene](https://cdn.targetmol.cn/group3/M00/02/65/CgoaEWY7LKeEcJWwAAAAAGm2G90541.png)

为众多的药物研发团队赋能,
让新药发现更简单!
Benzo[a]pyrene(3,4-Benzopyrene)在动物模型中表现出肺致癌性,常用于肺癌造模及化学预防研究。
| 规格 | 价格 | 库存 | 数量 |
|---|---|---|---|
| 1 mg | ¥ 117 | 现货 | |
| 5 mg | ¥ 238 | 现货 | |
| 10 mg | ¥ 339 | 现货 | |
| 25 mg | ¥ 749 | 现货 | |
| 50 mg | ¥ 1,100 | 现货 | |
| 100 mg | ¥ 1,610 | 现货 | |
| 200 mg | ¥ 3,060 | 现货 | |
| 1 mL x 10 mM (in DMSO) | ¥ 376 | 现货 |
| 产品描述 | Benzo[a]pyrene (3,4-Benzopyrene) exhibits lung carcinogenicity in animal models and is commonly used for lung cancer modeling and chemoprevention research. |
| 体内活性 | 在雌性A/J小鼠中,由Benzo[a]pyrene(B[a]P)引发的肺部肿瘤发生具有剂量依赖性。与对照组相比,接受0.25、0.50和1.0 mg B[a]P治疗的雌性小鼠的增生值发生率显著增高。接受1.0 mg B[a]P治疗的雌性小鼠中腺瘤的发生率显著高于对照组。接受0.50或1.0 mg B[a]P的雌性小鼠增生的多发性显著高于对照组。接受1.0 mg B[a]P治疗的组中腺瘤的多发性也显著高于对照组。B[a]P以剂量依赖的方式显著增加雌性A/J小鼠增生和腺瘤的发生率。肺部增生性病变被归类为支气管肺泡增生或腺瘤,未观察到恶性肿瘤(腺癌)[1]。 |
| 动物实验 | After a 1- or 2-week acclimatization period, 360 adult male A/J mice and 520 adult female A/J mice were used for the experiment.?Mice were allocated, using a body weight-based randomization process, to a total of 22 groups.?Briefly, each animal received a single intraperitoneal administration of one of the initiators, at one of the indicated doses, on day 1.?The animals were observed daily for clinical signs and mortality, and body weights were measured weekly.?Following an overnight fast at 26 weeks after dosing, all mice were anesthetized with sevoflurane and weighed.?They were then sacrificed by exsanguination from the abdominal aorta and caudal vena cava and subjected to necropsy[1]. |
| 别名 | 苯并[a]芘, 苯并(a)芘, 3,4-Benzopyrene |
| 分子量 | 252.31 |
| 分子式 | C20H12 |
| CAS No. | 50-32-8 |
| Smiles | C12=C3C4=CC=C1C=5C(C=C2C=CC3=CC=C4)=CC=CC5 |
| 密度 | 1.1549 g/cm3 (Estimated) |
| 存储 | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. | |||||||||||||||||||||||||
| 溶解度信息 | DMSO: 9.09 mg/mL (36.03 mM), Sonication is recommended. | |||||||||||||||||||||||||
| 体内实验配方 | 10% DMSO+40% PEG300+5% Tween 80+45% Saline: 1 mg/mL (3.96 mM), Sonication is recommended. 请按顺序添加溶剂,在添加下一种溶剂之前,尽可能使溶液澄清。如有必要,可通过加热、超声、涡旋处理进行溶解。工作液建议现配现用。以上配方仅供参考,体内配方并不是绝对的,请根据不同情况进行调整。 | |||||||||||||||||||||||||
溶液配制表 | ||||||||||||||||||||||||||
DMSO
| ||||||||||||||||||||||||||

Solution Structure of a Trans-Opened (10S)-dA Adduct of (+)-(7S,8R,9S,10R)-7,8-Dihydroxy-9,10-epoxy-7,8,9,10-tetrahydrobenzo[a]pyrene in a fully Complementary DNA Duplex
评论内容